


# PRECEDENT



## **PRECEDENT Study Overview**

Many women diagnosed with ovarian cancer initially receive a platinum-based chemotherapy such as cisplatin or carboplatin. Those women who develop a resistance to this therapy may then be treated with DOXIL® (also known as Peglyated Liposomal Doxorubicin, PLD, or CAELYX®).

The PRECEDENT Study is a Phase 2 clinical study evaluating the safety and effectiveness of EC145, an investigational drug (not approved by FDA), in combination with the standard therapy Doxil® compared to Doxil® alone.

## **About the PRECEDENT Study**

### Will I receive a placebo?

This study is designed so that every patient receives the approved standard therapy Doxil®. Approximately 2 in 3 patients will receive EC145 in combination with Doxil®. No patients will receive a placebo.

### Will I be charged for participating in the study?

There will be no charge to you for your participation in the study.

### What are the side effects of EC145?

EC145 is an investigational agent; therefore the side effects are still being studied. So far in early clinical studies, EC145 is generally well-tolerated. Talk with your physician about potential side effects.

### How can I find a clinical study site?

Participating sites are listed at [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Search for PRECEDENT ovarian.

### **Am I eligible for the PRECEDENT study?**

- Do you have ovarian cancer, fallopian tube cancer or primary peritoneal cancer?
- Has your disease progressed within 6 months of your first or second treatment with a platinum based chemotherapy drug (cisplatin or carboplatin)?
- Have you not been previously treated with Doxil®?


If so, you might be eligible to participate in the PRECEDENT clinical research study.

[To learn more about the study and/or eligibility requirements click here.](#)

## EC145-Targeted Therapy

The study drug EC145 is a new type of therapy called a targeted drug conjugate, which means that a drug is attached to a targeting ligand designed to attach to cancer cells. EC145 is a combination of folate (targeting ligand) and a chemotherapy drug. EC145 is being developed to deliver the chemotherapy directly to cancer cells which over-express the folate receptor.

EC145



## Folate Receptors and Cancer


Both normal and cancer cells need the vitamin folate (vitamin B-9) to function. Some rapidly dividing cancer cells demand more folate than their “normal” neighboring cells. These cancer cells use folate receptors to capture folate as it moves through the blood stream. It is theorized that cancer cells attract the folate in EC145 to their receptors where the chemotherapy drug is internalized and released into the cancer cell, leading to cell death. (Go to [www.endocyte.com](http://www.endocyte.com) and click on the animation to see folate-receptor targeting.)

**FolateScan (EC20) image of metastatic ovarian cancer patient whose tumor over-expresses folate-receptors.**

## Imaging Folate-Receptors (EC20)

Prior to starting treatment with EC145, subjects may have a nuclear medicine scan using an investigational (not approved by the FDA) imaging drug called FolateScan ( $^{99m}\text{Tc}$ -EC20). This image allows the study doctor to identify tumors that are most likely to “grab” EC145. This procedure has been performed in approximately 300 patients (with and without cancer) and has been found to be well tolerated.

For additional information about the PRECEDENT Study and general information about clinical studies, visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov). Search keyword phrase “PRECEDENT ovarian”.



“The content on this page summarizes current scientific and medical research being conducted by Endocyte. The drugs, EC20 and EC145, used in this study are investigational and are not available commercially. The safety and efficacy of this intervention has not been determined and this intervention has not been approved by FDA. No promotional claims about the products or product indications listed here should be inferred.”

The PRECEDENT study is sponsored by Endocyte.



3000 Kent Avenue  
West Lafayette, IN 47906  
765.463.7175  
[www.endocyte.com](http://www.endocyte.com)